The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Award of NF Mark

27 Feb 2013 08:39

RNS Number : 7711Y
Akers Biosciences, Inc.
27 February 2013
 



27 February 2013

 

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

French Certification for Disposable Breath Alcohol Detectors Received 

 

 

ABI, a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that further to the Company's announcement on 19 February 2013, ABI's proprietary disposable breath alcohol detectors have been granted the final award of the NF Marque ("NF Mark") number 18/01. The NF Mark enables the breathalysers be marketed and sold to consumers in and around France under the brand name CHUBE by ABI's UK based partner (en)10 (Global) Limited. This follows the Company's breath alcohol detector being deemed in compliance with the quality criteria defined in French Standard NF X 20-702 for disposable breathalysers by the national reference laboratory of France, Laboratoire National de Métrologie et d'Essais under Certificate 25024.

 

Thomas A. Nicolette, Chief Executive Officer of ABI, commented: "We are honored that our detector has been certified against the French Standard and are delighted that it now bears the prestigious NF Mark. Over the last ten months (en)10  and ABI have collaborated to develop a specific product for the French market that offers 100% accuracy and reliability. Inappropriate alcohol consumption isn't just a problem on the roads, it's a major public health issue worldwide. The current breathalyzer law in France is an opportunity to bring fresh thinking and a new product to the market that can help consumers to improved well-being by encouraging sustainable changes in their attitudes to alcohol consumption. Using CHUBE, with proven change programmes and modern consumer marketing, means a highly precise disposable, single use device is now available to the French consumer at a low enough price to encourage repeat use"

 

Enquiries:

 

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

 

Antony Legge or James Thomas

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc

Akers Biosciences develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

About (en)10 (Global) Ltd

Combining leading science innovations and clever design, (en)10 provides people the means to affect simple, precise, low-cost alcohol screening and the thinking, programmes and products to encourage broader, positive changes in attitudes to responsible alcohol consumption. It provides a fresh approach to achieving a healthy work culture and a more productive business: cutting costs and improving lives.  Additional information on the Company and its products can be found at www.en-10.com and at www.soyezchube.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAPAXADPDEEF
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.